Trevi Therapeutics Inc. (TRVI)
NASDAQ: TRVI
· Real-Time Price · USD
9.88
0.32 (3.35%)
At close: Oct 03, 2025, 3:59 PM
9.40
-4.86%
After-hours: Oct 03, 2025, 05:47 PM EDT
3.35% (1D)
Bid | 9.29 |
Market Cap | 1.2B |
Revenue (ttm) | 146K |
Net Income (ttm) | -47.3M |
EPS (ttm) | -0.45 |
PE Ratio (ttm) | -21.96 |
Forward PE | -19.12 |
Analyst | Buy |
Dividends | n/a |
Ask | 10 |
Volume | 1,243,285 |
Avg. Volume (20D) | 2,229,622.6 |
Open | 9.66 |
Previous Close | 9.56 |
Day's Range | 9.50 - 9.99 |
52-Week Range | 2.36 - 9.99 |
Beta | 0.74 |
Ex-Dividend Date | n/a |
About TRVI
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TRVI
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TRVI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
-5.85%
Trevi Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
4 months ago
-2.92%
TRVI stock has given up its prior gain. Trevi Therapeutics shares were trading higher after the company announced positive topline results from its Phase 2b CORAL trial of Haduvio.